Best overall tumor biomarker response for study participants reported as percentage of the baseline value. Responses are annotated for patient number, dose cohort, participant tumor type, KRAS mutation, tumor biomarker type and presence or absence of previously reported mKRAS-responsive HLA class I and II. * Patient 16 underwent excisional biopsy to assess iRECIST, and T cell infiltrate was observed; a contribution to ctDNA clearance could not be ruled out. ‘S’ indicates that the patient underwent splenectomy.
